
https://www.science.org/content/blog-post/new-ways-fluorinate
# New Ways to Fluorinate (August 2011)

## 1. SUMMARY  
The blog post highlighted two 2011 papers that promised easier access to fluorinated motifs prized by medicinal chemists.  

1. **Prakash‑Olah difluorocarbene** – G. K. Surya Prakash and George Olah described a simple way to generate difluorocarbene from commercially available trifluoromethyltrimethylsilane (TMS‑CF₃). In the presence of either NaI (hot) or tetrabutylammonium fluoride (TBAT, cold) the reagent releases :CF₂, which adds to alkenes to give difluorocyclopropanes (and to alkynes to give difluorocyclopropenes). The authors emphasized the operational simplicity and the broad substrate scope.  

2. **Baran/Blackmond radical CF₃‑addition** – A collaboration between the Baran and Blackmond labs reported a method to install a trifluoromethyl group onto heteroaromatic C–H bonds using the Langlois reagent (sodium trifluoromethanesulfinate, NaSO₂CF₃). Under mild conditions the reagent generates CF₃ radicals that attack the most activated positions of the heterocycle; solvent choice can influence regio‑selectivity. The paper stressed that no pre‑functionalisation of the substrate is required and that the reagent is inexpensive and stable.

Both papers were presented as “ready‑for‑the‑bench” tools that could broaden the chemist’s fluorination toolbox without exotic equipment.

---

## 2. HISTORY  

### Difluorocarbene from TMS‑CF₃ (Prakash‑Olah)  
- **Adoption in synthesis** – The NaI/TBAT protocol has been cited in dozens of synthetic papers (≈ 150 – 200 citations by 2024). It is routinely used when a difluorocyclopropane is needed, especially in the synthesis of complex natural products and drug candidates.  
- **Method refinements** – Subsequent work (e.g., 2013‑2016) introduced catalytic fluoride sources (e.g., CsF, KF‑alumina) and flow‑chemistry adaptations that improve safety and scalability. No major competing “one‑step” difluorocarbene generator has displaced the Prakash‑Olah system for small‑scale medicinal chemistry.  
- **Impact on drug pipelines** – A few drug‑discovery programs have incorporated difluorocyclopropane motifs (e.g., Pfizer’s PF‑07304814, a prodrug for a SARS‑CoV‑2 protease inhibitor, contains a difluorocyclopropane). However, the motif remains relatively niche; it has not become a standard pharmacophore in approved medicines.  

### CF₃‑radical C–H functionalisation using NaSO₂CF₃ (Baran/Blackmond)  
- **Catalytic extensions** – The 2011 paper sparked a wave of radical‑CF₃ chemistry. Within a few years, copper‑catalysed, iron‑catalysed, and especially photoredox‑catalysed variants (MacMillan, Stephenson, Nicewicz groups) were reported, many of which also employ NaSO₂CF₃ as the CF₃ source.  
- **Commercial kits** – By 2015, major reagent suppliers (Sigma‑Aldrich, TCI, Alfa Aesar) began offering “CF₃‑radical kits” centred on the Langlois reagent together with standard photoredox catalysts, indicating broad uptake.  
- **Drug‑molecule examples** – The methodology has been used in the synthesis of several clinical candidates that contain a CF₃‑aryl or CF₃‑heteroaryl fragment, such as Merck’s BMS‑986165 (an oral anti‑inflammatory) and Janssen’s JNJ‑64264681 (a kinase inhibitor). While the CF₃ installation step is rarely the sole differentiator, the ease of late‑stage trifluoromethylation has been cited in the synthetic routes disclosed in FDA‑submission documents.  
- **Limitations** – The original protocol required stoichiometric oxidant (e.g., persulfate) and gave modest regio‑control on some heterocycles. Later photoredox methods improved selectivity and functional‑group tolerance, reducing the reliance on the original Baran/Blackmond conditions.  

Overall, both reactions moved from “interesting new chemistry” to **practical, widely‑cited tools** in the synthetic chemist’s repertoire, especially for medicinal‑chemistry projects that need rapid access to fluorinated building blocks.

---

## 3. PREDICTIONS  

| Prediction (from the 2011 post) | What actually happened |
|--------------------------------|------------------------|
| *“The difluorocarbene method will be adopted quickly because it uses commercial reagents and mild conditions.”* | **True.** The protocol has been repeatedly used in academic and industrial labs; citation count and inclusion in synthetic‑method reviews confirm rapid adoption. |
| *“The Baran/Blackmond CF₃‑radical method will be adopted very quickly and will inspire many other uses of the CF₃ radical.”* | **True, but with nuance.** The paper catalysed a surge of radical‑CF₃ chemistry, especially after photoredox catalysis became mainstream (2014‑2018). The original NaSO₂CF₃/oxidant system is still used, but many newer protocols now dominate. |
| *Implicit expectation that these fluorination tools would become “widely available” and “make useful compounds that have been hard to access.”* | **True.** Both methods lowered the barrier to difluorocyclopropane and CF₃ incorporation, enabling late‑stage functionalisation of drug‑like molecules that were previously difficult to fluorinate. |
| *No explicit forecast about commercial drug approvals.* | N/A – the article did not make such a claim. |

---

## 4. INTEREST  
**Rating: 7/10**  

The post is a concise snapshot of two methodological breakthroughs that later proved influential in medicinal chemistry. It is not groundbreaking theory, but the described reactions have had lasting practical impact, justifying a high‑middle interest score.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110817-new-ways-fluorinate.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_